1 Wall Street Analyst Sees Spacex's Stock Soaring by Over 450%. What Are the Chances of It Happening?

SpaceX shares are down 28% from the all-time high as of the July 13 open after its June 12 IPO raised $75B at a $1.77T initial valuation and a $135 IPO price. A Raymond James analyst (Brian Gesuale) set an $800 target, implying a 452% gain from ~$145 (and $10.5T market cap vs ~$1.9T today), which would require ~19% annual returns over 10 years to be plausible. The article argues near-term upside is capped by the IPO’s lofty valuation and that price action is driven more by hype/speculation than near-term fundamentals.

Analysis

This is a valuation-discounting event, not a new operating datapoint. When a newly public hyper-growth name starts to trade below the psychology of its issue price, marginal demand shifts from long-only growth funds to faster money, and the stock begins behaving like a long-duration call option on flawless execution. That usually benefits proven cash-flow compounders in adjacent innovation baskets, while punishing any peer still priced primarily on optionality rather than monetization.

Near term, the real catalyst is the first reporting cycle and any disclosure on backlog conversion, customer concentration, and capex discipline. If the company cannot show a credible path to free cash flow, the market will compress the multiple even if revenue growth remains high; there is little valuation cushion for launch slippage, regulatory friction, or a single operational miss. The important reversal trigger is not a higher analyst target, but evidence that the business can self-fund growth without repeated dilution.

The consensus is overfocusing on a heroic endpoint and underweighting the rate at which risk budgets rotate away from stories with long payback periods. That matters because the same capital can be redeployed into better-underwritten growth elsewhere, especially names with visible monetization and margin leverage. The bearish view fails only if execution converts the narrative into near-term financial visibility within the next 12-18 months; absent that, upside is likely capped by the sheer amount of perfection embedded in the current setup.

Key Decisions for Investors

• Avoid initiating a fresh long in SPCX at current levels; treat it as a show-me story until the first post-IPO earnings print confirms backlog conversion and gross margin trajectory. Risk/reward is poor unless you are underwriting 12-18 months of flawless execution.
• If borrow/liquidity is workable, fade strength in SPCX with 3-6 month put spreads rather than outright short stock. The payoff is cleaner because the downside thesis is multiple compression, while the main risk is a momentum squeeze on any contract or launch headline.
• Pair trade: long NVDA / short SPCX for a relative-value rotation out of long-duration optionality into proven monetization. Use a 1-2 quarter horizon; thesis breaks if SPCX shows accelerating free-cash-flow visibility or if NVDA multiple compression resumes on macro de-risking.
• Set an alert for the first guidance update and any disclosure around customer concentration or capex intensity. If management signals self-funding growth within 12-18 months, cover bearish exposure immediately; that would invalidate the valuation-bubble thesis.